Back to Search Start Over

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity

Authors :
Arne Søraas
Gunnveig Grødeland
Beathe Kiland Granerud
Thor Ueland
Andreas Lind
Børre Fevang
Sarah L. Murphy
Camilla Huse
Anders Benteson Nygaard
Anne Katrine Steffensen
Huda al-Baldawi
Mona Holberg-Petersen
Lise Lima Andresen
Camilla Ågnes
Trine Ranheim
Ylva Schanke
Mette Istre
John Arne Dahl
Adity Chopra
Susanne Dudman
Mari Kaarbø
Jan Terje Andersen
Eline Benno Vaage
Trung The Tran
John Torgils Vaage
Annika E. Michelsen
Fredrik Müller
Pål Aukrust
Bente Halvorsen
Tuva B. Dahl
Jan Cato Holter
Fridtjof Lund-Johansen
Source :
Frontiers in Immunology, Vol 13 (2022)
Publication Year :
2022
Publisher :
Frontiers Media S.A., 2022.

Abstract

BackgroundResults showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals.MethodsWe measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively.FindingsInfection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters.InterpretationThe results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant.FundingThe study was funded by the Oslo University Hospital, and by grants from The Coalition for Epidemic Preparedness Innovations, Research Council of Norway (no 312780, 324272), South-Eastern Norway Regional Health Authority (no 2019067, 2021071, 10357, 2021047, 33612, 2021087, 2017092), EU Horizon 2020 grant no 848099, a philantropic donation from Vivaldi Invest A/S, and The European Virus Archive Global.

Details

Language :
English
ISSN :
16643224
Volume :
13
Database :
Directory of Open Access Journals
Journal :
Frontiers in Immunology
Publication Type :
Academic Journal
Accession number :
edsdoj.b48aae54e3e14b67ad888efba97122e0
Document Type :
article
Full Text :
https://doi.org/10.3389/fimmu.2022.964525